HAMILTON, ON and BOSTON, May 31, 2023
/PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a
clinical-stage oncology company focused on developing
next-generation radiopharmaceuticals as precision medicines, today
announced that the Company will present in a fireside chat at the
Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 04:00 p.m. ET. Presenting on behalf of Fusion
will be Chief Executive Officer John
Valliant, Ph.D.
A live webcast of the event will be available on the "Events and
Presentations" page in the "Investors & Media" section of the
Company's website at https://ir.fusionpharma.com/events-webcasts. A
replay of the webcast will be archived on the Company's website for
90 days following the presentation.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company
focused on developing next-generation radiopharmaceuticals as
precision medicines. Fusion connects alpha particle emitting
isotopes to various targeting molecules to selectively deliver the
alpha emitting payloads to tumors. Fusion's clinical portfolio
includes: FPI-2265 targeting prostate specific membrane antigen
(PSMA) for metastatic castration resistant prostate cancer
currently in a Phase 2 trial; FPI-1434 targeting insulin-like
growth factor 1 receptor currently in a Phase 1 trial; and
FPI-2059, a small molecule targeting neurotensin receptor 1
(NTSR1), currently in a Phase 1 trial. In addition to a robust
proprietary pipeline, Fusion has a collaboration with AstraZeneca
to jointly develop novel targeted alpha therapies (TATs) and
combination programs between Fusion's TATs and AstraZeneca's DNA
Damage Response Inhibitors (DDRis) and immuno-oncology agents. The
Company recently received IND clearance for FPI-2068, the first
novel TAT under the collaboration, which targets EGFR-cMET. Fusion
has also entered into a collaboration with Merck to evaluate
FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in
patients with solid tumors expressing IGF-1R. To support Fusion's
growing pipeline of TATs, the Company has signed strategic actinium
supply agreements with TRIUMF, Niowave, Inc. and BWXT Medical.
Contact:
Amanda
Cray
Senior Director of Investor Relations & Corporate
Communications
(617) 967-0207
cray@fusionpharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-jefferies-healthcare-conference-301839109.html
SOURCE Fusion Pharmaceuticals